MARKET WIRE NEWS

FibroBiologics Inc. (NASDAQ : FBLG) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.


Quote


Last:$0.8752
Change Percent: 6.73%
Open:$0.8
Close:$0.82
High:$0.8799
Low:$0.8
Volume:120,594
Last Trade Date Time:06/30/2026 12:45:40 pm

Stock Data


Market Cap:$17,774,070
Float:39,126,900
Insiders Ownership:0.21%
Institutions:18
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.fibrobiologics.com
Country:US
City:Houston

Recent News Releases


Subscribe to Our Newsletter

**MWN-AI FAQ is based on asking OpenAI questions about FibroBiologics Inc. (NASDAQ: FBLG).

Link Market Wire News to Your X Account

Download The Market Wire News App